Qilian International Holding Group Limited (QLI) Stock
Qilian International Holding Group Limited (QLI), founded in 2019 and headquartered in Jiuquan, People's Republic of China, focuses on the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMDs), and a variety of other products. The company's diverse offerings include licorice-derived products such as Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, supplied to pharmaceutical companies for manufacturing traditional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient for producing compound licorice oral solutions.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Qilian International Holding Group Limited
Qilian International Holding Group Limited (QLI), founded in 2019 and headquartered in Jiuquan, People's Republic of China, focuses on the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMDs), and a variety of other products. The company's diverse offerings include licorice-derived products such as Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, supplied to pharmaceutical companies for manufacturing traditional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient for producing compound licorice oral solutions. QLI also produces Qilian Shan oxytetracycline tablets, used to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and humans, alongside Qilian Shan oxytetracycline APIs for other pharmaceutical manufacturers. Its TCMD line features Ahan antibacterial paste, designed for addressing stubborn chronic skin ailments. Furthermore, the company provides heparin sodium preparations to pharmaceutical firms for developing medications related to cardiovascular diseases, cerebrovascular conditions, and hemodialysis. Beyond the medical sector, Qilian International offers Zhu Xiaochang natural sausage casings for culinary applications. In agriculture, it produces Xiongguan organic fertilizers, formulated to improve crop yield, enhance soil chemical properties, and reduce compaction, as well as Xiongguan organic-inorganic compound fertilizers to stimulate plant growth.
Qilian International Holding Group Limited is headquartered in CN.
Qilian International Holding Group Limited (QLI) stock trades at $5.41 with a market capitalization of $38.68M. The stock is valued at a negative price-to-earnings (P/E) ratio of -24.59, reflecting a net loss over the last twelve months, price-to-book of 4.52, price-to-sales of 0.83. Over the past 52 weeks the stock has ranged between $1.78 and $6.69, and currently trades 19.1% below its 52-week high.
On profitability, Qilian International Holding Group Limited generates a return on equity (ROE) of -16.24% (negative, reflecting a net loss), return on capital employed of -5.85%, an operating margin of -5.62%, a net profit margin of -16.74%.
Official website: www.qlsyy.net
Related Healthcare Stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.